Literature DB >> 2901784

Effect of acid inhibition on Campylobacter pylori.

M Blanco1, J M Pajares, M L Jimenez, M Lopez-Brea.   

Abstract

Campylobacter pylori (Cp) infection has been demonstrated in 59 of 65 (91%) patients with gastric or duodenal ulcer. Patients were included in a double blind study with ranitidine or famotidine for 4-8 weeks. After therapy, all gastric and duodenal ulcers healed but Cp remained in all previously infected patients, associated with chronic inflammation of gastric mucosa. Our results suggest that H2 antagonists do not have any effect either on Cp infection or on concurrent chronic gastritis. At the same time we observed that Cp infection does not disturb the ulcer healing process. However, Cp may be implicated in the persistence of the chronic gastritis and relapses of ulcers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901784

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  3 in total

Review 1.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 2.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

3.  Helicobacter pylori in duodenal ulcer patients with idiopathic gastric acid hypersecretion.

Authors:  M J Collen; R M Strong
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.